GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (NEOE:BMND) » Definitions » Interest Coverage
中文

Biomind Labs (NEOE:BMND) Interest Coverage

: No Debt (1) (As of Sep. 2023)
View and export this data going back to 2021. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Biomind Labs's Operating Income for the three months ended in Sep. 2023 was C$-0.18 Mil. Biomind Labs's Interest Expense for the three months ended in Sep. 2023 was C$0.00 Mil. Biomind Labs has no debt. The higher the ratio, the stronger the company's financial strength is.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Biomind Labs's Interest Coverage or its related term are showing as below:


NEOE:BMND's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 135.52
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Biomind Labs Interest Coverage Historical Data

The historical data trend for Biomind Labs's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biomind Labs Annual Data
Trend Dec21 Dec22
Interest Coverage
- -

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only No Debt - No Debt No Debt No Debt

Competitive Comparison

For the Biotechnology subindustry, Biomind Labs's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Biomind Labs's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Interest Coverage falls into.



Biomind Labs Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biomind Labs's Interest Coverage for the fiscal year that ended in Dec. 2022 is calculated as

Here, for the fiscal year that ended in Dec. 2022, Biomind Labs's Interest Expense was C$-0.00 Mil. Its Operating Income was C$-3.99 Mil. And its Long-Term Debt & Capital Lease Obligation was C$0.00 Mil.

Biomind Labs did not have earnings to cover the interest expense.

Biomind Labs's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the three months ended in Sep. 2023, Biomind Labs's Interest Expense was C$0.00 Mil. Its Operating Income was C$-0.18 Mil. And its Long-Term Debt & Capital Lease Obligation was C$0.00 Mil.

Biomind Labs had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Biomind Labs  (NEOE:BMND) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Biomind Labs Interest Coverage Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs (NEOE:BMND) Business Description

Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs (NEOE:BMND) Headlines

No Headlines